Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 16,553 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers

Turmeric and Turmeric-containing Tablets and Sebum Production

NCT03065504
Conditions
Skin Inflammation
Interventions
Turmeric, Turmeric-containing combination tablet, Placebo tablets
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Sacramento, California
Conditions
Metastatic Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Tumor
Interventions
Talazoparib, ASTX727
Drug
Lead sponsor
Kathy Miller
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Indianapolis, Indiana • Winston-Salem, North Carolina
Conditions
Psoriatic Arthritis
Interventions
Guselkumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Rezular 15mg, Placebo, Rezular
Drug
Lead sponsor
AGI Therapeutics, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Wilmington, North Carolina
Conditions
Juvenile Idiopathic Arthritis
Interventions
methotrexate prefilled pen
Device
Lead sponsor
medac GmbH
Industry
Eligibility
2 Years to 20 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Kansas City, Missouri
Completed Not applicable Interventional Results available

Persona TM Tibia Clinical Outcomes Study

NCT03589300
Conditions
Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Collagen Disorders and/or Avascular Necrosis of the Femoral Condyle, Post-traumatic Loss of Joint Configuration, Moderate Valgus, Varus, or Flexion Deformities
Interventions
Persona TM Tibia
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Torrance, California • Wheat Ridge, Colorado • Honolulu, Hawaii + 4 more
Conditions
Brain Tumors, Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Lymphoma, Nausea, Vomiting, Neuroblastoma, Ovarian Cancer, Sarcoma
Interventions
electroacupuncture therapy, sham intervention, quality-of-life assessment
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
5 Years to 35 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Scabies
Interventions
Spinosad Topical
Drug
Lead sponsor
Cipher Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 4 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Miami, Florida • Lafayette, Louisiana • Houston, Texas
Conditions
Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC)
Interventions
EXS74539
Drug
Lead sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Los Angeles, California • Fort Worth, Texas • West Valley City, Utah
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
HER-2/neu peptide vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Breast Cancer, Upper Extremity Lymphedema
Interventions
QBX258
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer, Bone Metastases
Interventions
Skeletal Scintigraphy, Radiography, CT Scan
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Conditions
HER2-positive Breast Cancer, Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Neratinib, Trastuzumab, Loperamide, Crofelemer, Diphenoxylate/Atropine
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Francisco, California
Conditions
Breast Cancer, Sleep Hygiene
Interventions
Sleep Hygiene Training
Behavioral
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Toledo, Ohio
Conditions
Mastectomy, Breast Cancer
Interventions
Liposomal bupivacaine, Standard bupivacaine, Placebo
Drug · Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Breast Cancer
Interventions
KW-2450 in combination with lapatinib and letrozole
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Long Beach, California • Los Angeles, California • Deerfield Beach, Florida + 2 more
Conditions
Breast Cancer, Indolent Metastatic Breast Cancer
Interventions
Exercise Intervention
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
New Haven, Connecticut • Avon, Indiana • Carmel, Indiana + 2 more
Conditions
Triple Negative Breast Cancer (TNBC)
Interventions
Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl, nab-Paclitaxel, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, Avelumab, ALT-803, haNK, Cyclophosphamide, Doxorubicin HCL, paclitaxel
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
El Segundo, California
Conditions
Lymphedema, Musculoskeletal Complications, Radiation Fibrosis, Radiation Toxicity, Sarcoma
Interventions
Chemotherapy, Radiation therapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
14
States / cities
Newark, Delaware • Gainesville, Florida • Jacksonville, Florida + 11 more
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study to Evaluate Optical Spectroscopy of Pigmented Skin Lesions

NCT00633516
Conditions
Skin Cancer
Interventions
Optical Spectroscopy
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Irvine, California • Orange, California
Conditions
Diabetic Foot Ulcers
Interventions
ofloxacin, MSI-78
Drug
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1996
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
Lomvastomig
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Completed Phase 2 Interventional Results available

Miltefosine to Treat Mucocutaneous Leishmaniasis

NCT01050907
Conditions
Mucosal Leishmaniasis, Cutaneous Leishmaniasis
Interventions
Miltefosine
Drug
Lead sponsor
Knight Therapeutics (USA) Inc
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Fabry Disease
Interventions
Replagal
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland